Hopstem Biotech

Hopstem Biotechnology Co., Ltd. was founded in January 2017, by neuroscientists and stem-cell biologists from the Johns Hopkins University. Hopstem holds world-leading expertise in neural differentiation, cell banking and cell engineering of human-induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). The major aims of our company are to apply these cutting edge technologies to promote biomedical research, diagnoses, and therapies of neurological and other disorders.

Our products include different types of high quality human neuronal cells, 2D and 3D models of human nervous system diseases, neural stem cell culture, differentiation, and maturation reagents, cell line establishing services. We are also open to collaborations on biomarker and drug discovery, including drug screening and neurotoxicity testing, as well as clinical trials of neural progenitor cell transplantation in ischemic stroke and brain injury.

Hopstem values innovation and quality as the most fundamental bases of a biotechnology company.